RBC Capital Rates Viridian Therapeutics (VRDN) buy

Analyst Lisa Walter kept a buy rating and a $35 price target on the biotech developer on June 30, 2026, a 90.53% upside from the current price.

By TradeTexts Research Desk · Published Jul 1, 2026, 3:02 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $35 price target on June 30, 2026.

Since the rating, $VRDN is up 11.4% after 1 week, up 8.3% after 1 month and up 3.6% to date (from the $18.37 close on Jun 30, 2026).

VRDN Viridian Therapeutics, Inc.

$19.03 -37.97% year to date

Daily close · Oct 16, 2026

Key Points

RBC Capital analyst Lisa Walter reiterated a buy rating on Viridian Therapeutics with a $35 price target on June 30, 2026.
RBC Capital's $35 price target implies 90.53% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.37 share price.
The stock recently traded near $18.37, moving inside a 52-week range spanning from $13.18 up to $34.29.
A total of 16 analyst opinions currently shape a consensus mean price target of $36.63 for the healthcare company.

Get $VRDN trade alerts by text

We text you when insiders, Congress or big funds trade $VRDN. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures

RBC Capital Reaffirms View on Viridian Therapeutics

On June 30, 2026, RBC Capital analyst Lisa Walter reiterated a buy rating on Viridian Therapeutics, Inc. (NasdaqCM: VRDN) with a $35.00 price target. The update arrives as Wall Street follows progress across the company's clinical pipeline for rare and serious diseases.

Analyst rating track record

RBC Capital vs. the S&P 500

YTD return +8.42% hypothetical

All-time return +12.25% S&P 500 +30.84%

vs. S&P 500 -18.59% behind the index

Hypothetical returns from RBC Capital's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the biotech developer through the summer and fall. On June 30, 2026, Truist Securities maintained a buy rating while adjusting its price target to $38.00 from $35.00. On the same date, Wedbush maintained an outperform rating and lifted its target to $43.00 from $32.00, while Needham kept a buy rating with a target of $34.00 up from $32.00. Wells Fargo later joined the coverage pool on June 29, 2026, with an upgrade to Overweight and a $31.00 target. Additional updates arrived on August 7, 2026, when Truist Securities maintained its buy rating at a $39.00 target and RBC Capital maintained its outperform rating at $36.00. RBC Capital updated its view again on September 22, 2026, keeping an outperform rating while moving its target to $38.00. Across the broader professional community, 16 analyst opinions shape a consensus mean price target of $36.63, with individual targets stretching from a low of $22.00 up to a high of $50.00.

Stock Price Context and Market Range

Shares of Viridian Therapeutics recently changed hands around $18.37. The equity has moved through a 52-week trading window defined by a low point of $13.18 and a high of $34.29. With a market capitalization near $2.44 billion, the biotechnology firm operates with a current ratio of 16.95 and a quick ratio of 16.56, showing solid short-term liquidity relative to its debt obligations.

12-month forecast

$VRDN price target

Viridian Therapeutics, Inc. daily closes and this analyst's $35 target. Not advice.

Advancing Treatments for Rare Diseases

Headquartered in Waltham, Massachusetts, Viridian Therapeutics focuses on discovering, developing, and commercializing novel therapies for serious conditions. Its clinical pipeline centers on IGF-1R therapies designed to treat thyroid eye disease, featuring candidates such as Veligrotrug and Elegrobart. The research team also works on treatments for Graves' disease and engineered inhibitors of the neonatal Fc receptor to improve patient outcomes.

What to Watch at Viridian Therapeutics, Inc.

Market participants are looking forward to the company's next scheduled earnings report on November 5, 2026, for further updates on clinical trials and pipeline execution. Analyst targets and firm ratings will likely shift as new data from ongoing medical studies becomes available.